Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Fineline Cube Jul 17, 2026
Company Drug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Fineline Cube Jul 17, 2026
Company Deals

GSC to Distribute Hecin’s Innovative PCR and RT-PCR Solutions in Middle Eastern Markets

Fineline Cube Aug 23, 2024

Gulf Scientific Corporation (GSC), a prominent life sciences service provider headquartered in Dubai, United Arab...

Company

WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report

Fineline Cube Aug 23, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China,...

Company Drug

Innovent Biologics’ Fulzerasib Receives NMPA Approval for Advanced NSCLC Treatment in China

Fineline Cube Aug 23, 2024

Innovent Biologics Inc., a biopharmaceutical company based in China and listed on the Hong Kong...

Policy / Regulatory

China’s NHC and NHSA Intensify Efforts to Stabilize Drug Supply and Prices Amid Shortages

Fineline Cube Aug 22, 2024

The National Health Commission (NHC) has published a report titled “Recent Work on Securing Supply...

Policy / Regulatory

China Commits to Optimizing Market Access for Emerging Sectors and Global Scientific Collaboration

Fineline Cube Aug 22, 2024

The General Office of the Communist Party of China (CPC) Central Committee and the State...

Company Drug

Qilu Pharmaceutical’s Biosimilar Ranibizumab Receives NMPA Approval, Marking a First in China

Fineline Cube Aug 22, 2024

Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its biosimilar version of Novartis’s blockbuster...

Company Drug

BrightGene Bio Receives FDA Clearance for Generic Eribulin APIs, Advancing in Breast Cancer Treatment

Fineline Cube Aug 22, 2024

BrightGene Bio-Medical Technology Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...

Company

Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches

Fineline Cube Aug 22, 2024

Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released...

Company Drug

Daiichi Sankyo Launches Tarlige for Diabetes Peripheral Neuropathic Pain in China

Fineline Cube Aug 22, 2024

Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has announced the official market launch...

Company Deals

Changchun GeneScience Pharmaceutical Expands Reach with HuChuang Union Partnership

Fineline Cube Aug 22, 2024

Changchun GeneScience Pharmaceutical Co., Ltd, a Chinese pharmaceutical enterprise, has established a partnership with HuChuang...

Company Deals

SynthAsia and Shanghai General Hospital Partner to Advance Diabetic Retinopathy Research

Fineline Cube Aug 22, 2024

SynthAsia has forged a strategic partnership with Shanghai General Hospital, focusing on scientific innovation within...

Company

Jiangsu Hengrui Pharmaceuticals Reports 21.78% YOY Revenue Growth and 48.67% Increase in Net Profit for H1 2024

Fineline Cube Aug 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China with shares traded...

Drug

Akeso Biopharma’s Ivonescimab Earns Category 1 Recommendation in China’s 2024 Lung Cancer Clinical Guideline

Fineline Cube Aug 22, 2024

Akeso Biopharma, a China-based pharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 9926),...

Company Drug

Hangzhou Biosunpharma’s OB756 New Drug Application Accepted for Myelofibrosis Treatment by China’s NMPA

Fineline Cube Aug 22, 2024

Hangzhou Biosunpharma Co., Ltd. has announced that the National Medical Products Administration (NMPA) has accepted...

Company

R&D Investments and Operating Cash Flows Highlight Resilience in Simcere Pharma’s H1 2024 Financial Report

Fineline Cube Aug 22, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has reported its financial results for the first...

Company Policy / Regulatory

US Congressmen Call for FDA Investigation into Clinical Trials at China’s Military Hospitals

Fineline Cube Aug 22, 2024

US lawmakers are intensifying their scrutiny of the involvement of Chinese military hospitals in hosting...

Company Drug

Jiangsu Hansoh and GSK Receive FDA Breakthrough Designation for B7-H3 Targeted ADC in Small-Cell Lung Cancer

Fineline Cube Aug 22, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a prominent Chinese pharmaceutical company, and its UK...

Company Deals

Henlius Biotech Secures Exclusive Rights to Commercialize Convalife’s Generic Neratinib in China and Abroad

Fineline Cube Aug 22, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has entered...

Company

WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant

Fineline Cube Aug 22, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals Medical Device

Bone Index Secures Financing to Expand Manufacturing and Promote Diagnostic Technology Globally

Fineline Cube Aug 22, 2024

Bone Index, a Finland-based medical technology company specializing in bone diagnostics, has announced the successful...

Posts pagination

1 … 340 341 342 … 696

Recent updates

  • Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression
  • Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy
  • Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs
  • Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients
  • Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Company Drug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Company Drug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Company Drug

Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.